Phase II Study of First-line Amrubicin in Elderly Patients with Extensive Disease Small-Cell Lung Cancer (CJLSG1104)
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2015
Price : $35 *
At a glance
- Drugs Amrubicin (Primary) ; Granulocyte colony-stimulating factors
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 14 Dec 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 15 Jan 2013 New trial record
- 07 Jan 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.